Literature DB >> 25371202

Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Arangassery Rosemary Bastian1, Aakansha Nangarlia1, Lauren D Bailey2, Andrew Holmes2, R Venkat Kalyana Sundaram1, Charles Ang1, Diogo R M Moreira3, Kevin Freedman4, Caitlin Duffy2, Mark Contarino2, Cameron Abrams4, Michael Root5, Irwin Chaiken6.   

Abstract

Entry of HIV-1 into host cells remains a compelling yet elusive target for developing agents to prevent infection. A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis. We found that gold nanoparticle-conjugated forms of peptide triazoles (AuNP-PT) exhibit substantially more potent antiviral effects against HIV-1 than corresponding peptide triazoles alone. Here, we sought to reveal the mechanism of potency enhancement underlying nanoparticle conjugate function. We found that altering the physical properties of the nanoparticle conjugate, by increasing the AuNP diameter and/or the density of PT conjugated on the AuNP surface, enhanced potency of infection inhibition to impressive picomolar levels. Further, compared with unconjugated PT, AuNP-PT was less susceptible to reduction of antiviral potency when the density of PT-competent Env spikes on the virus was reduced by incorporating a peptide-resistant mutant gp120. We conclude that potency enhancement of virolytic activity and corresponding irreversible HIV-1 inactivation of PTs upon AuNP conjugation derives from multivalent contact between the nanoconjugates and metastable Env spikes on the HIV-1 virus. The findings reveal that multispike engagement can exploit the metastability built into virus the envelope to irreversibly inactivate HIV-1 and provide a conceptual platform to design nanoparticle-based antiviral agents for HIV-1 specifically and putatively for metastable enveloped viruses generally.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Drug Design; Gold Nanoparticles; Human Immunodeficiency Virus (HIV); Microbicide; Nanotechnology; Peptides; Virology; Virolysis; p24 Release

Mesh:

Substances:

Year:  2014        PMID: 25371202      PMCID: PMC4281754          DOI: 10.1074/jbc.M114.608315

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

2.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode.

Authors:  Khaled A Mahmoud; John H T Luong
Journal:  Anal Chem       Date:  2008-08-16       Impact factor: 6.986

4.  Virolysis and in vitro neutralization of HIV-1 by humanized monoclonal antibody hNM-01.

Authors:  M Nakamura; M Terada; H Sasaki; M Kamada; T Ohno
Journal:  Hybridoma       Date:  2000-12

5.  Update of the drug resistance mutations in HIV-1: March 2013.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Gunthard; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2013 Feb-Mar

6.  Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

Authors:  Richard E Nettles; Dirk Schürmann; Li Zhu; Michele Stonier; Shu-Pang Huang; Ih Chang; Caly Chien; Mark Krystal; Megan Wind-Rotolo; Neelanjana Ray; George J Hanna; Richard Bertz; Dennis Grasela
Journal:  J Infect Dis       Date:  2012-08-14       Impact factor: 5.226

7.  Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.

Authors:  Karyn McFadden; Patricia Fletcher; Fiorella Rossi; Muddagowda Umashankara; Vanessa Pirrone; Srivats Rajagopal; Hosahudya Gopi; Fred C Krebs; Julio Martin-Garcia; Robin J Shattock; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

8.  Highly active antiretroviral treatment for the prevention of HIV transmission.

Authors:  Reuben Granich; Siobhan Crowley; Marco Vitoria; Ying-Ru Lo; Yves Souteyrand; Christopher Dye; Charlie Gilks; Teguest Guerma; Kevin M De Cock; Brian Williams
Journal:  J Int AIDS Soc       Date:  2010-01-12       Impact factor: 5.396

9.  Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.

Authors:  Felix G Hermann; Lisa Egerer; Frances Brauer; Christian Gerum; Harald Schwalbe; Ursula Dietrich; Dorothee von Laer
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

View more
  10 in total

Review 1.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

2.  Targeting cell surface HIV-1 Env protein to suppress infectious virus formation.

Authors:  Arangassery Rosemary Bastian; Charles G Ang; Kantharaju Kamanna; Farida Shaheen; Yu-Hung Huang; Karyn McFadden; Caitlin Duffy; Lauren D Bailey; Ramalingam Venkat Kalyana Sundaram; Irwin Chaiken
Journal:  Virus Res       Date:  2017-04-06       Impact factor: 3.303

3.  Peptide-Based HIV Entry Inhibitors.

Authors:  Jing Pu; Qian Wang; Shibo Jiang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

Review 5.  Metal-Based Nanoparticles for the Treatment of Infectious Diseases.

Authors:  Blessing Atim Aderibigbe
Journal:  Molecules       Date:  2017-08-18       Impact factor: 4.411

Review 6.  Nanotechnology for virus treatment.

Authors:  Jiarong Zhou; Nishta Krishnan; Yao Jiang; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Today       Date:  2020-12-01       Impact factor: 20.722

7.  Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.

Authors:  Shiyu Zhang; Andrew P Holmes; Alexej Dick; Adel A Rashad; Lucía Enríquez Rodríguez; Gabriela A Canziani; Michael J Root; Irwin M Chaiken
Journal:  Retrovirology       Date:  2021-10-09       Impact factor: 3.768

Review 8.  Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development.

Authors:  Agnieszka Staśkiewicz; Patrycja Ledwoń; Paolo Rovero; Anna Maria Papini; Rafal Latajka
Journal:  Front Chem       Date:  2021-05-20       Impact factor: 5.221

9.  Peptide Triazole Thiol Irreversibly Inactivates Metastable HIV-1 Env by Accessing Conformational Triggers Intrinsic to Virus-Cell Entry.

Authors:  Charles Gotuaco Ang; Erik Carter; Ann Haftl; Shiyu Zhang; Adel A Rashad; Michele Kutzler; Cameron F Abrams; Irwin M Chaiken
Journal:  Microorganisms       Date:  2021-06-12

Review 10.  The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation.

Authors:  May Griffith; Mohammad M Islam; Joel Edin; Georgia Papapavlou; Oleksiy Buznyk; Hirak K Patra
Journal:  Front Bioeng Biotechnol       Date:  2016-09-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.